Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
NCT06228482Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium lu 177-dota-abm-5g in non-small cell lung cancer (NSCLC), sponsored by University of California, Davis. Primary endpoints: [68Ga]Ga DOTA-5G PET/CT imaging at 2 hours, [177Lu]Lu DOTA-ABM-5G treatment safety at 30 days and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
lutetium lu 177-dota-abm-5g
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06228482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228482.